SecBot SecBot
PRESS-RELEASE ·Filed Mar 23, 2026

PYXS

Pyxis Oncology
MIXED
Impact 6/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

Investors should focus on the mid-2026 data readout for MICVO monotherapy with modified dosing, which could validate improved safety and sustained efficacy. The cash runway into Q4 2026 suggests potential need for financing if development accelerates.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$1.42
T+0 close · Mar 23, 2026 · via day close
Latest settled
+33.80%
T+60 · $1.90
Vs SPY
+20.74%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 23 $1.42entry
  2. T+1 · 8mo ago −4.23%α −3.87% · $1.36
  3. T+5 · 8mo ago −10.56%α −7.00% · $1.27
  4. T+20 · 7mo ago +20.42%α +13.00% · $1.71
  5. T+60 · 5mo ago +33.80%α +20.74% · $1.90
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Pyxis Oncology reported financial results for 2025 and provided a clinical update on its lead asset, micvotabart pelidotin (MICVO), in head and neck cancer. The company completed enrollment in its Phase 1 monotherapy dose expansion study and expects updated data mid-2026. Preliminary data showed strong response rates, but revenues declined year-over-year due to lower milestone and royalty income. The company has sufficient cash to fund operations into Q4 2026.

Key Financial Metrics

Revenue
$13.9M
-14.1% YoY
Adj. EPS
$-1.09
GAAP: $-1.28

Key Facts

  • Completed target enrollment in Phase 1 monotherapy dose expansion study of MICVO in 2L+ R/M HNSCC in Q1 2026
  • Preliminary monotherapy data: 46% ORR and 92% DCR in 13 efficacy-evaluable patients
  • Combination with KEYTRUDA®: 71% ORR and 100% DCR in 7 patients
  • Revenues decreased to $13.9M in 2025 from $16.1M in 2024
  • R&D expenses increased to $73.7M from $58.7M in 2024
  • Net loss widened to $79.6M in 2025 from $77.3M in 2024
  • Cash and short-term investments totaled $68.3M as of Dec 31, 2025, funding operations into Q4 2026
  • Appointed Thomas Civik as Interim CEO in February 2026

Financial Impact

Revenue declined by 13.7% YoY to $13.9M, while R&D spending increased by $15M. Net loss widened slightly despite lower G&A costs.

revenuer&d_expensenet_losscash_runway

Risk Factors

  • Clinical data is based on small patient numbers (n=13 monotherapy, n=7 combination)
  • Revenue decline reflects reliance on non-recurring milestone and royalty sales
  • Increased R&D spend without near-term commercial revenue increases financial risk
  • Dosing modifications may not improve safety in larger cohorts

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3260234

Track record

25 reports on PYXS

Performance horizon

6 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +42.94% at T+60 after the Apr 17, 2026 report. 8 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.43 Now $1.41 −1.32% settles Dec 16
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $1.43 Now $1.41 −1.40% settles Dec 16
  3. Nov 16, 2026today SC 13G Neutral 4/10 Entry $1.55 Now $1.41 −9.14% settles Dec 15
  4. Nov 5, 202611d ago 8-K Neutral 5/10 Entry $1.61 Now $1.41 −12.42% settles Dec 4
  5. Nov 3, 202613d ago SC 13G/A Bearish 5/10 Entry $1.64 Now $1.41 +14.02% settles Dec 2
  6. Oct 27, 202620d ago Press Release Neutral 4/10 Entry $1.84 Now $1.41 −23.37% settles Nov 24
  7. Oct 21, 202626d ago DEF 14A Bearish 6/10 Entry $1.71 Now $1.41 +17.54% settles Nov 19
  8. Oct 9, 20265w ago SC 13G/A Neutral 4/10 Entry $2.03 to $1.66 Now $1.41 −30.54% ▼ −18.23% −12.67% vs SPY
  9. Oct 2, 20266w ago SC 13G/A Neutral 4/10 Entry $2.14 to $1.81 Now $1.41 −34.11% ▼ −15.42% −13.61% vs SPY
  10. Oct 2, 20266w ago Press Release Bearish 7/10 Entry $2.14 to $1.81 Now $1.41 +34.11% ▲ +15.42% +13.61% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 23, 2026